News | June 09, 2024
Ecolab and Repligen launch DurA Cycle affinity resin for biologic manufacturing
DurA Cycle is designed for large-scale commercial manufacturing of monoclonal antibodies,
DurA Cycle is designed for large-scale commercial manufacturing of monoclonal antibodies,
Ashkenazi will continue to serve at full capacity in her role and as a member of Lilly's Executive Committee through July 2024
Updated analysis from Memorial Sloan Kettering Cancer Center presented at ASCO 2024 has expanded to 42 patients with clinical complete response
Dual immunotherapy combination of Opdivo plus Yervoy demonstrated improved survival benefit compared to lenvatinib or sorafenib in this patient population
Recommendation based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months
The companies have initiated Phase 3 studies in patients with high-risk melanoma and non-small cell lung cancer
The Indian pharmaceutical industry is projected to reach US$ 130 billion by 2030
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
Ulcerative Colitis (UC) is a chronic, idiopathic, immune-mediated inflammatory bowel disease (IBD) affecting the large intestine
Acceptance based on results demonstrated a statistically significant improvement in overall survival versus chemotherapy alone in these patients
Subscribe To Our Newsletter & Stay Updated
